Lisa Cronin
Overview
Explore the profile of Lisa Cronin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
413
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Judge P, Tuttle K, Staplin N, Hauske S, Zhu D, Sardell R, et al.
Nephrol Dial Transplant
. 2024 Nov;
PMID: 39533115
Patients with chronic kidney disease (CKD) are at risk of progressive loss of kidney function, heart failure, and cardiovascular death despite current proven therapies, including renin-angiotensin system inhibitors (RASi), sodium...
2.
Bornstein S, de Zeeuw D, Heerspink H, Schulze F, Cronin L, Wenz A, et al.
Diabetes Obes Metab
. 2024 Mar;
26(6):2128-2138.
PMID: 38497241
Aim: This Phase I study evaluated the safety and early efficacy of an aldosterone synthase inhibitor (BI 690517) in people with diabetes and albuminuric chronic kidney disease. Methods: Double-blind, placebo-controlled...
3.
Tuttle K, Hauske S, Canziani M, Caramori M, Cherney D, Cronin L, et al.
Lancet
. 2023 Dec;
403(10424):379-390.
PMID: 38109916
Background: Excess aldosterone accelerates chronic kidney disease progression. This phase 2 clinical trial assessed BI 690517, an aldosterone synthase inhibitor, for efficacy, safety, and dose selection. Methods: This was a...
4.
Tuttle K, Rossing P, Hauske S, Cronin L, Hussain J, de Zeeuw D, et al.
Am J Nephrol
. 2023 Oct;
55(2):262-272.
PMID: 37903483
Introduction: Aldosterone synthase (AS) inhibition may overcome increased aldosterone production in response to renin-angiotensin system inhibition. BI 690517 is an AS inhibitor under investigation for chronic kidney disease (CKD). Methods:...
5.
Del Brutto V, Diener H, Easton J, Granger C, Cronin L, Kleine E, et al.
J Am Heart Assoc
. 2022 Jun;
11(11):e023545.
PMID: 35656979
Background We sought to determine recurrent stroke predictors among patients with embolic strokes of undetermined source (ESUS). Methods and Results We applied Cox proportional hazards models to identify clinical features...
6.
Bahit M, Sacco R, Easton J, Meyerhoff J, Cronin L, Kleine E, et al.
Circulation
. 2021 Oct;
144(22):1738-1746.
PMID: 34649459
Background: A proportion of patients with embolic stroke of undetermined source have silent atrial fibrillation (AF) or develop AF after the initial evaluation. Better understanding of the risk for development...
7.
Toyoda K, Uchiyama S, Hagihara Y, Kuwashiro T, Mori T, Kamiyama K, et al.
Circ J
. 2020 Nov;
84(12):2286-2295.
PMID: 33132228
Background: The international Randomized, Double-Blind, Evaluation in Secondary Stroke Prevention Comparing the EfficaCy and Safety of the Oral Thrombin Inhibitor Dabigatran Etexilate versus Acetylsalicylic Acid in Patients with Embolic Stroke...
8.
Diener H, Sacco R, Easton J, Granger C, Bar M, Bernstein R, et al.
Stroke
. 2020 May;
51(6):1758-1765.
PMID: 32404035
Background and Purpose- The RE-SPECT ESUS trial (Randomized, Double-Blind, Evaluation in Secondary Stroke Prevention Comparing the Efficacy and Safety of the Oral Thrombin Inhibitor Dabigatran Etexilate Versus Acetylsalicylic Acid in...
9.
Diener H, Sacco R, Easton J, Granger C, Bernstein R, Uchiyama S, et al.
N Engl J Med
. 2019 May;
380(20):1906-1917.
PMID: 31091372
Background: Cryptogenic strokes constitute 20 to 30% of ischemic strokes, and most cryptogenic strokes are considered to be embolic and of undetermined source. An earlier randomized trial showed that rivaroxaban...
10.
Halton J, Lehr T, Cronin L, Lobmeyer M, Haertter S, Belletrutti M, et al.
Thromb Haemost
. 2016 Jul;
116(3):461-71.
PMID: 27357738
Venous thromboembolism (VTE) incidence is increasing among children owing to many factors, including improved diagnosis of VTE. There is a need for alternative treatment options. Our objective was to investigate...